Findings

What do systematic reviews say?

11 questions · 11 findings · 5 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 72.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 9.1%Moderate 2 · 18.2%High 0 · 0%

Outpatient vs inpatient treatment

Long‐term all‐cause mortality · people with low‐risk acute pulmonary embolism

Outpatient showed no clear difference in long‐term all‐cause mortality compared with inpatient treatment (low certainty).

1 finding from 1 review

Outpatient versus inpatient treatment for acute pulmonary embolism 2022 · Cochrane Headline outcomes only
RR 0.98 [0.06, 15.58]
2 studies · 451 participants
Low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Mortality ‐ intermediate and long term · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in mortality ‐ intermediate and long term compared with BMP plus placebo (moderate certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 0.48 [0.21, 1.06]
3 studies · 649 participants
Moderate

Low molecular weight heparin vs vitamin K antagonist (VKA)

Mortality (treatment duration 3 months) · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE

LMWH showed no clear difference in mortality (treatment duration 3 months) compared with VKA (moderate certainty).

1 finding from 1 review

Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous… 2017 · Cochrane Headline outcomes only
Peto OR 1.08 [0.75, 1.56]
16 studies · 3299 participants
Moderate

Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (long term)

All‐cause mortality · people who underwent a lower limb revascularisation

The review found no eligible studies for this question.

1 finding from 1 review

Duplex ultrasound for surveillance of lower limb revascularisation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Berotralstat vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avoralstat vs placebo

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nanofiltered C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lanadelumab vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found